scholarly journals Comparing the immunogenicity and safety of 3 Japanese encephalitis vaccines in Asia-Pacific area: A systematic review and meta-analysis

2015 ◽  
Vol 11 (6) ◽  
pp. 1418-1425 ◽  
Author(s):  
Shi-Yuan Wang ◽  
Xiao-Hua Cheng ◽  
Jing-Xin Li ◽  
Xi-Yan Li ◽  
Feng-Cai Zhu ◽  
...  
Keyword(s):  
Systematic Review ◽  
Japanese Encephalitis ◽  
Meta Analysis ◽  
Asia Pacific ◽  
Pacific Area

Comparison of immunogenicity and safety of licensed Japanese encephalitis vaccines: A systematic review and network meta-analysis

Vaccine ◽  
2021 ◽  
Author(s):  
Luis Furuya-Kanamori ◽  
Chang Xu ◽  
Suhail A.R. Doi ◽  
Justin Clark ◽  
Kinley Wangdi ◽  
...  
Keyword(s):  
Systematic Review ◽  
Japanese Encephalitis ◽  
Meta Analysis

scholarly journals Global prevalence of hidradenitis suppurativa and geographical variation—systematic review and meta-analysis

2020 ◽  
Vol 4 (1) ◽  
Author(s):  
Kevin Phan ◽  
Olivia Charlton ◽  
Saxon D. Smith
Keyword(s):  
Systematic Review ◽  
Significant Variation ◽  
Hidradenitis Suppurativa ◽  
Meta Analysis ◽  
Asia Pacific ◽  
Cochrane Library ◽  
Prevalence Rates ◽  
Level Of Evidence ◽  
Pooled Prevalence ◽  
The Usa

Abstract Background There is a significant variation in the reported prevalence of hidradenitis suppurativa (HS), ranging from 0.03–4%. We hypothesized that this significant variation may be due to different prevalence rates of HS according to geographical location as well as sex. Objective We aimed to perform a meta-analysis to determine pooled overall prevalence of HS, prevalence stratified according to geographical region and sex. Materials and methods A systematic review was performed by searching Ovid Medline, PubMed, Cochrane Library, DARE, and Embase, from inception to August 2018. A systematic review and meta-analysis was performed according to PRISMA guidelines. A meta-analysis of proportions was performed to determined pooled prevalence rates, with meta-regression based on geographic region. Prevalence in males versus females was also performed according to region. Results The overall pooled prevalence rate was 0.3% (0.2–0.6%) based on 118,760,093 HS cases available. Subgroup analysis demonstrated prevalence differences, with the highest being in Europe 0.8% (0.5–1.3%), compared to the USA 0.2% (0.1–0.4%), Asia-Pacific 0.2% (0.01–2.2%), and South America 0.2% (0.01–0.9%). Prevalence in males was lower compared to females in the USA (OR 0.403, 95% CI 0.37–0.439, P < 0.001) as well as in Europe (OR 0.635, 95% CI 0.397–1.015, P = 0.08) but not in the Asia-Pacific region (OR 0.936, 95% CI 0.319–2.751, P = 0.78). Conclusion Prevalence of HS varies significantly according to the geographical population. This variation is likely attributed to different ethnicity distributions amongst different continents. Level of evidence III

Obesity and mortality in patients with esophageal cancer: A systematic review and meta-analysis.

2016 ◽  
Vol 34 (4_suppl) ◽  
pp. 20-20
Author(s):  
Arjun Gupta ◽  
Kaustav Majumder ◽  
Nivedita Arora ◽  
Preet Paul Singh ◽  
Siddharth Singh
Keyword(s):  
Systematic Review ◽  
Esophageal Cancer ◽  
Subgroup Analysis ◽  
Observational Studies ◽  
Meta Analysis ◽  
Asia Pacific ◽  
Limited Data ◽  
Inconsistency Index ◽  
All Cause Mortality ◽  
Never Smokers

20 Background: Obesity influences incidence of esophageal cancer (EC) with contrasting impact on esophageal adenocarcinoma (EAC) and esophageal squamous cell carcinoma (ESC). However, it is unclear whether it influences mortality in patients with EC. We performed a systematic review and meta-analysis to assess the association between obesity and EC mortality. Methods: Through a systematic search of major databases and conference proceedings, up to June 2015, we identified observational studies reporting the association between obesity (premorbid body mass index [BMI] ≥ 30 kg/m2) and all-cause mortality in patients with EC. We estimated summary adjusted hazard ratio (aHR) with 95% confidence intervals (CI), comparing highest BMI category with reference category in each study using random effects model; heterogeneity was measured using the inconsistency index (I2). Results: We identified 8 studies (including 1 pooled cohort study) with 2,784,027 people, of whom 18% were obese. On meta-analysis, compared with EC patients with reference BMI, obese EC patients had aHR for mortality of 0.97 (95% CI, 0.66-1.43), with high heterogeneity (I2 = 88%) after pooling maximally adjusted HRs. On analyzing patients with EAC alone (3 studies), mortality aHR was 1.10 (95% CI, 0.43-2.82), with high heterogeneity (I2 = 95%). Data to separately analyze ESC or to perform subgroup analysis in males vs females, smokers vs never smokers and Asia Pacific vs Western populations was limited. Conclusions: Based on meta-analysis, obesity does not appear to be associated with mortality in patients with EC. However, high heterogeneity and limited data for subgroup analysis limits the interpretation of this analysis. Further prospective studies evaluating mortality in patients with established EC are needed to answer this question. [Table: see text]

Vaccination against Japanese encephalitis with IC51: systematic review on immunogenicity, duration of protection and safety

2020 ◽  
Vol 27 (2) ◽  
Author(s):  
Kerstin Kling ◽  
Thomas Harder ◽  
Zane Younger ◽  
Gerd Burchard ◽  
Jonas Schmidt-Chanasit ◽  
...  
Keyword(s):  
Systematic Review ◽  
Japanese Encephalitis ◽  
Meta Analysis ◽  
Age Groups ◽  
Risk Groups ◽  
The Body ◽  
Trial Methodology ◽  
Serious Adverse Events ◽  
Clinical Trial Methodology ◽  
Randomized Studies

Abstract Japanese encephalitis is a disease caused by a flavivirus which is transmitted by mosquitos in endemic countries. Considering the potentially severe outcomes of the disease, vaccination is recommended for those at risk of exposure. During recent years, IC51 (IXIARO®, JESPECT®, JEVAL®) has increasingly been used to protect travellers from Europe and the USA. However, no systematic review exists that summarizes the currently available evidence on the immunogenicity and safety of this vaccine. We conducted a systematic review on the immunogenicity and safety of IC51, using the databases PubMed, MEDLINE, EMBASE and ClinicalTrials.gov (search date: 31 August 2019). Data extracted from included studies were grouped by outcomes and stratified by population and setting. Risk of bias (ROB) was assessed using the RoB 2 tool for randomized controlled trials (RCTs) and ROBINS-I for non-randomized studies. Due to high heterogeneity, meta-analysis was not performed. A total of 32 studies from 16 countries met the inclusion criteria (15 RCTs, 17 non-randomized studies). ROB was serious or high in the majority of studies. Seroprotection rates ranged from 93 to 100% in adults (seven studies) and from 91 to 100% in children (four studies). In the study involving adults aged 64 years and older, seroprotection was 65% with higher rates in persons who were previously vaccinated against tick-borne encephalitis virus. Safety was investigated in 27 studies. Rates of serious adverse events were below 5% in all age groups, with the majority not being causally related to the vaccine. IC51 is a safe vaccine with good seroprotective abilities in persons aged &gt;2 months to &lt;64 years. The body of evidence, however, is weakened by a large amount of heterogeneity in study and clinical trial methodology. Further well-designed RCTs with special risk groups are needed.

scholarly journals Domestic Violence During the COVID-19 Pandemic: A Systematic Review

2021 ◽  
pp. 152483802110386
Author(s):  
Anastasia Kourti ◽  
Androniki Stavridou ◽  
Eleni Panagouli ◽  
Theodora Psaltopoulou ◽  
Chara Spiliopoulou ◽  
...  
Keyword(s):  
Systematic Review ◽  
Domestic Violence ◽  
Social Services ◽  
Asia Pacific ◽  
Prevention Measures ◽  
School Closures ◽  
International Trends ◽  
Perpetrators And Victims ◽  
Present Systematic Review ◽  
Pacific Area

Background: COVID-19 outbreak and the followed confinement measures have raised concerns to specialists worldwide regarding the imminent increase in domestic violence cases. The present systematic review aims to identify the international trends in domestic violence during the COVID-19 epidemic and to examine the possible differences among all population groups and different geographic areas worldwide. Method: The following databases were accessed: DOAJ, ERIC, Google Scholar, ProQuest, Pubmed, PsycNet, and SCOPUS, up to July 22, 2020. Results: A total of 32 studies were considered eligible. Data from North America, Europe, Asia-Pacific Area, Africa, and worldwide researches were retrieved. COVID-19 has caused an increase in domestic violence cases, especially during the first week of the COVID-19 lockdown in each country. In children, however, although the specialists’ estimations suggested an increase in child maltreatment and abuse cases, the rate of police and social services’ reports has declined during the COVID-19 pandemic. School closures that isolated students at home seemed to have contributed to this decrease. Conclusions: Domestic violence has been a considerable issue imposed by the COVID-19 epidemic to a worldwide context. The home confinement led to constant contact between perpetrators and victims, resulting in increased violence and decreased reports. In order to minimize such issues, prevention measures and supporting programs are necessary.

Are all vaccines safe for the pregnant traveller? A systematic review and meta-analysis

2019 ◽  
Vol 27 (2) ◽  
Author(s):  
Roni Nasser ◽  
Stav Rakedzon ◽  
Yaakov Dickstein ◽  
Amjad Mousa ◽  
Ido Solt ◽  
...  
Keyword(s):  
Systematic Review ◽  
Adverse Events ◽  
Pregnant Women ◽  
Yellow Fever ◽  
Japanese Encephalitis ◽  
Observational Studies ◽  
Hepatitis A ◽  
Meta Analysis ◽  
Meningococcal Vaccines ◽  
Tick Borne Encephalitis

Abstract Pregnant travellers and their offspring are vulnerable to severe outcomes following a wide range of infections. Vaccine-preventable diseases can have a particularly severe course in pregnant women, but little is known about the safety of travel vaccines in pregnant women. We performed a systematic review of all published literature concerning the safety of vaccines frequently given to travellers such as yellow fever, MMR (mumps, measles and rubella), influenza, Tdap (tetanus, diphtheria and pertussis), meningococcus, hepatitis A and B, rabies, polio, typhoid fever, tick-borne encephalitis and Japanese encephalitis vaccines. We included case series, cohort studies and randomized controlled trials (RCTs). For the meta-analysis, we included only RCTs that compared the administration of a vaccine to placebo or to no vaccine. Outcome measures included severe systemic adverse events, maternal outcomes related to the course of pregnancy, neonatal outcomes and local adverse events. We calculated the risk ratio and its 95% confidence interval as the summary measure. The safety of influenza vaccine is supported by high-quality evidence. For Tdap vaccine, no evidence of any harm was found in the meta-analysis of RCTs. A slight increase in chorioamnionitis rate was reported in 3 out of 12 observational studies. However, this small possible risk is far outweighed by a much larger benefit in terms of infant morbidity and mortality. Meningococcal vaccines are probably safe during pregnancy, as supported by RCTs comparing meningococcal vaccines to other vaccines. Data from observational studies support the safety of hepatitis A, hepatitis B and rabies vaccines, as well as that of the live attenuated yellow fever vaccine. We found little or no data about the safety of polio, typhoid, Japanese encephalitis, tick-borne encephalitis and MMR vaccines during pregnancy.

Sign in / Sign up

Export Citation Format

Share Document